Phase I/II clinical trial of modified vaccinia virus Ankara (MVA) [TBC-MVA; smallpox vaccine; Therion Biologics] to evaluate its safety, immunogenicity and protective efficacy against Dryvax [smallpox vaccine] challenge in vaccinia-immune individuals

Trial Profile

Phase I/II clinical trial of modified vaccinia virus Ankara (MVA) [TBC-MVA; smallpox vaccine; Therion Biologics] to evaluate its safety, immunogenicity and protective efficacy against Dryvax [smallpox vaccine] challenge in vaccinia-immune individuals

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2007

At a glance

  • Drugs Smallpox vaccine (Primary)
  • Indications Smallpox
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Mar 2007 Status change from in progress to completed.
    • 09 Feb 2007 Results have been reported.
    • 08 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top